Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs
Jazyk angličtina Země Scotland Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
15894512
DOI
10.1016/j.drup.2005.04.006
PII: S1368-7646(05)00032-4
Knihovny.cz E-zdroje
- MeSH
- adukty DNA metabolismus MeSH
- antitumorózní látky farmakologie MeSH
- chemorezistence * MeSH
- cisplatina farmakologie MeSH
- DNA metabolismus MeSH
- nádorový supresorový protein p53 fyziologie MeSH
- NF-kappa B fyziologie MeSH
- oprava DNA MeSH
- organoplatinové sloučeniny farmakologie MeSH
- rekombinace genetická MeSH
- telomery MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- adukty DNA MeSH
- antitumorózní látky MeSH
- BBR 3464 MeSH Prohlížeč
- cisplatina MeSH
- DNA MeSH
- nádorový supresorový protein p53 MeSH
- NF-kappa B MeSH
- organoplatinové sloučeniny MeSH
- transplatin MeSH Prohlížeč
The importance of platinum drugs in cancer chemotherapy is underscored by the clinical success of cisplatin [cis-diamminedichloroplatinum(II)] and its analogues and by clinical trials of other, less toxic platinum complexes that are active against resistant tumors. The antitumor effect of platinum complexes is believed to result from their ability to form various types of adducts with DNA. Nevertheless, drug resistance can occur by several ways: increased drug efflux, drug inactivation, alterations in drug target, processing of drug-induced damage, and evasion of apoptosis. This review focuses on mechanisms of resistance and sensitivity of tumors to conventional cisplatin associated with DNA modifications. We also discuss molecular mechanisms underlying resistance and sensitivity of tumors to the new platinum compounds synthesized with the goal to overcome resistance of tumors to established platinum drugs. Importantly, a number of new platinum compounds were designed to test the hypothesis that there is a correlation between the extent of resistance of tumors to these agents and their ability to induce a certain kind of damage or conformational change in DNA. Hence, information on DNA-binding modes, as well as recognition and repair of DNA damage is discussed, since this information may be exploited for improved structure-activity relationships.
Citace poskytuje Crossref.org
Platinum nanoparticles induce damage to DNA and inhibit DNA replication
DNA adducts of antitumor cisplatin preclude telomeric sequences from forming G quadruplexes
Biophysical studies on the stability of DNA intrastrand cross-links of transplatin
Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog